CoChat

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Open access

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Significance: A better mechanistic understanding of the survival benefits and identification of biomarkers of response would greatly enhance the optimal utilization of antiangiogenic agents such as bevacizumab in combination with chemotherapy in the treatment of cancer. This study indicates that the benefits of bevacizumab with chemotherapy in non–small cell lung cancer (NSCLC) patients may depend on tumor vascular function during treatment. These correlative studies also provide new insights into the selection of NSCLC patients most likely to benefit from the addition of bevacizumab treatment to chemotherapy. The imaging and circulating biomarker candidates should be further evaluated in larger studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1424024112

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 129

Metadata

Authors
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., Gandhi, L., Lynch, T. J., Engelman, J. A., & Jain, R. K.
Affiliations
  • Departments of aMedicine,
  • Radiation Oncology, and
  • Harvard University (US)
  • Department of Medical Oncology, University of Arizona Cancer Center at Dignity, Phoenix, AZ 85013;
  • Cleveland Clinic (US)
  • Stanford Cancer Institute (US)
  • Dana-Farber Cancer Institute (US)
  • Yale Cancer Center (US)
Venue
Proceedings of the National Academy of Sciences
Published
2015-01-20
Volume
112
Issue
5
Pages
1547-1552
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1981486151
Cited by
126
References
34
Citations by year
2026: 2 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 9 · 2021: 12 · 2020: 13 · 2019: 11 · 2018: 17 · 2017: 25 · 2016: 16 · 2015: 12
FWCI
10.14
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
  • HHS | NIH | National Cancer Institute (P01CA080124, R01CA159258)
  • U.S. Department of Defense (W81XWH-10-1-0016)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
bevacizumab, anti-VEGF therapy, non-small cell lung cancer, carboplatin, nab-paclitaxel, tumor vascularization, vascular rarefaction, vascular permeability, placental growth factor, soluble VEGFR1, treatment resistance biomarkers, dynamic contrast-enhanced CT, plasma cytokines, progression-free survival, combination chemotherapy
MeSH terms
Bevacizumab, Albumins, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neovascularization, Pathologic, Biomarkers, Tumor, Carboplatin, Paclitaxel, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.